CompletedNot Applicable

Topical Ganciclovir Versus Systemic Aciclovir in the Treatment of Herpetic Keratitis

Egypt20 participantsStarted 2024-10-01

Plain-language summary

Traditional antiviral treatments, including systemic acyclovir, have shown effectiveness in resolving keratitis but can also lead to complications, including ocular surface toxicity and the development of acyclovir-resistant strains of HSV. Topical ganciclovir 0.15% ophthalmic gel presents a safer alternative for managing herpetic keratitis, offering effective viral suppression with minimal toxicity. This study aims to compare the efficacy and safety of topical ganciclovir versus systemic acyclovir in treating herpetic keratitis, providing valuable insights into optimal management strategies for this condition

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients diagnosed with herpetic keratitis Exclusion Criteria: * Patients with known allergies to ganciclovir or acyclovir * Severe ocular surface disease * Those who have previously received antiviral therapy for herpetic keratitis within the last month

What they're measuring

Corneal healing

Timeframe: At 4 and 6 weeks

Trial details

NCT IDNCT06757907

SponsorAl-Azhar University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-20

View on ClinicalTrials.gov More Herpetic Keratitis trials